Icon Plc (ICLR) Forecasted to Post Q4 2017 Earnings of $1.41 Per Share

Icon Plc (NASDAQ:ICLR) – Analysts at Jefferies Group decreased their Q4 2017 earnings per share (EPS) estimates for shares of Icon in a report issued on Tuesday. Jefferies Group analyst D. Windley now anticipates that the medical research company will earn $1.41 per share for the quarter, down from their previous estimate of $1.42. Jefferies Group currently has a “Buy” rating and a $132.00 target price on the stock. Jefferies Group also issued estimates for Icon’s Q1 2018 earnings at $1.40 EPS, Q2 2018 earnings at $1.47 EPS, Q3 2018 earnings at $1.57 EPS, Q4 2018 earnings at $1.64 EPS, FY2018 earnings at $6.07 EPS and FY2019 earnings at $6.72 EPS.

Other equities analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Icon from a “buy” rating to a “hold” rating in a research report on Wednesday. KeyCorp reaffirmed a “buy” rating and set a $130.00 price target on shares of Icon in a research report on Thursday. ValuEngine lowered shares of Icon from a “buy” rating to a “hold” rating in a research report on Monday, October 2nd. Barclays upped their price target on shares of Icon from $108.00 to $120.00 and gave the stock an “equal weight” rating in a research report on Friday, October 27th. Finally, Robert W. Baird reaffirmed a “buy” rating and set a $123.00 price target on shares of Icon in a research report on Thursday, October 12th. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. Icon presently has an average rating of “Buy” and a consensus target price of $121.82.

Icon (ICLR) opened at $117.81 on Thursday. Icon has a 52-week low of $76.46 and a 52-week high of $124.48. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.90 and a current ratio of 1.90. The company has a market cap of $6,370.00, a P/E ratio of 22.88, a P/E/G ratio of 1.63 and a beta of 0.61.

Icon (NASDAQ:ICLR) last issued its quarterly earnings results on Thursday, October 26th. The medical research company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.32 by $0.03. Icon had a net margin of 16.37% and a return on equity of 28.42%. The firm had revenue of $440.30 million during the quarter, compared to analyst estimates of $438.09 million. During the same quarter in the prior year, the business posted $1.19 earnings per share. Icon’s revenue for the quarter was up 4.8% compared to the same quarter last year.

Several institutional investors have recently added to or reduced their stakes in ICLR. Koch Industries Inc. increased its position in shares of Icon by 17,508.8% in the second quarter. Koch Industries Inc. now owns 666,140 shares of the medical research company’s stock worth $659,000 after acquiring an additional 662,357 shares in the last quarter. FMR LLC increased its position in shares of Icon by 38.4% in the second quarter. FMR LLC now owns 2,291,005 shares of the medical research company’s stock worth $224,037,000 after acquiring an additional 635,950 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Icon by 48.4% in the second quarter. Janus Henderson Group PLC now owns 1,068,159 shares of the medical research company’s stock worth $104,488,000 after acquiring an additional 348,292 shares in the last quarter. Mckinley Capital Management LLC Delaware increased its position in shares of Icon by 2,674.8% in the second quarter. Mckinley Capital Management LLC Delaware now owns 338,520 shares of the medical research company’s stock worth $33,104,000 after acquiring an additional 326,320 shares in the last quarter. Finally, Principal Financial Group Inc. increased its position in shares of Icon by 71.5% in the third quarter. Principal Financial Group Inc. now owns 768,471 shares of the medical research company’s stock worth $87,513,000 after acquiring an additional 320,356 shares in the last quarter. 89.66% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Icon Plc (ICLR) Forecasted to Post Q4 2017 Earnings of $1.41 Per Share” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.themarketsdaily.com/2018/01/11/icon-plc-iclr-forecasted-to-post-q4-2017-earnings-of-1-41-per-share.html.

Icon Company Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Earnings History and Estimates for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply